Twist Bioscience Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 24.64% Barclays $45 → $60 Maintains Overweight 06/13/2024 35.02% TD Cowen $55 → $65 Maintains B
Expert Outlook: Nurix Therapeutics Through The Eyes Of 14 Analysts
In the last three months, 14 analysts have published ratings on Nurix Therapeutics (NASDAQ:NRIX), offering a diverse range of perspectives from bullish to bearish.The table below summarizes their rece
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 23.99% RBC Capital $23 → $26 Maintains Outperform 06/18/2024 23.99% HC Wainwright & Co. $19 → $
Cathie Wood's Top and Bottom Performing ARKK Holdings of H1
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.
Intellia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 213.71% Canaccord Genuity $73 → $73 Maintains Buy 06/24/2024 179.33% Cantor Fitzgerald $65 → $6
Why Recursion Pharmaceuticals Stock Is Tumbling Thursday
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower Thursday after the company announced a proposed offering of its common stock.What Happened: Recursion announced that it intends to
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
6 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:IONS) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates th
Market-Moving News for June 27th
CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Proposal To Acquire Its China Business For Aggregate Purchase Price Of $40MME
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Thursday.Shares of Levi Strauss & Co. (NYSE:LEVI) fell sharply in today's pre-market trading after the compan
Ionis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 10.46% Stifel $50 → $53 Maintains Hold 06/14/2024 — Bernstein Upgrades Underperform → Market P
CRISPR Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 55.37% Needham $88 → $88 Reiterates Buy → Buy 06/17/2024 85.39% Piper Sandler $105 → $105 Reite
Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN), amidst a volatile market.
Recursion Pharmaceuticals Stock Is Diving Wednesday: What's Going On?
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower in Wednesday's after-hours session after the company announced a proposed offering of its common stock.What Happened: After the mar
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
On Tuesday, June 25, 2024, Cathie Wood-led Ark Invest made significant trades in NVIDIA Corp (NASDAQ:NVDA) and Roku Inc (NASDAQ:ROKU), amidst considerable market volatility. These trades were part of
Ionis Gains as Anti-lipid Therapy Undergoes FDA Priority Review
Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Cathie Wood's Ark Sells Over 41M Ginkgo Shares
Recursion Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/25/2024 78.01% Needham $17 → $17 Reiterates Buy → Buy 05/10/2024 78.01% Needham $17 → $17 Reiterates Bu